Amicus Therapeutics Announces Reimbursement of Galafold® (migalastat) for Treatment of Fabry Disease

Fabry Australia is very pleased to announce on 1st November 2018, Amicus Therapeutics (Nasdaq: FOLD) announced that the Australian Government has approved funding for the oral precision medicine Galafold® (migalastat) on the Life Saving Drugs Program (LSDP), for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation. The read Full Press Release Press Here.


+61 (0)412 462 732

Fabry Australia Inc.  |  ABN 70 053 079 595  | Registered Number A0029817E
Terms & Conditions